Reference | No. | Fraction size (Gy) | Total dose (Gy) | Target of RT | Response (%) | Median Survival (months) | RILD (%) | Grade III toxicity | Combined therapy |
---|---|---|---|---|---|---|---|---|---|
McIntosh [19] | 20 | 2.5 | 50 | PVTT(+) 40 % | PR 6.2 | 9.6 | N/A | UGI bleeding 1/20 | Capecitabine |
 |  |  | PVTT(−) 60 % | SD 87.5 |  |  |  |  | |
Chi [34] | 23 | 2.5–4.5 | 52.5 (median) | N/A | CR 8.6 | 16 | 1/23 | UGI bleeding 2/23 | Sunitinib |
 |  |  |  | PR 65.4 |  |  | Hematology 6/23 |  | |
Kim [14] | 35 | 4.5–6 | 50 (range, 45–60) | PVTT(+) 100 % | CR 14.3 | 12.9 | 0/35 | GI bleeding 2/35 | Capecitabine |
 |  |  |  | PR 28.6 | Responder 13.9 |  | Hematology 3/35 |  | |
 |  |  |  |  | Non-responder 6.9 |  |  |  | |
Kong [15] | 20 | 1.8–4 | 50–57.5 (range, 30–60) | PVTT(+) 36.4 % | CR 18.2 | 14.4 | 1/20 | None | None |
 |  |  | PVTT(−) 63.6 % | PR 54.5 | Responder 87.8a |  |  |  | |
 |  |  |  |  |  | Non-responder 65.6a |  |  |  |
Current study | 38 | 1.8–2.4 | 54 (range, 46–71.8) | PVTT(+) 63.2 % | CR 5.2 | 12.6 | 1/38 | 1/38 | None |
 |  |  | PVTT(−) 36.5 % | PR 47.4 | Responder 27.8 |  |  |  | |
 |  |  |  |  |  | Non-responder 6.2 |  |  |  |